Annual General Meeting and Corporate Governance
Indoco Remedies Limited will hold its 79th Annual General Meeting on September 17, 2026 via video conference to approve audited standalone and consolidated financial statements for FY 2025-26. Key agenda items include declaration of final dividend of ₹0.20 per equity share, re-appointment of Aditi Panandikar as Managing Director for five years, continuation of Vasudha V Kamat as Independent Director beyond 75 years, and approval to increase borrowing limits to ₹1,500 crores. Remote e-voting will be available from September 13-16, 2026 with CS Ajit Sathe appointed as scrutinizer.
Financial Performance Overview
Indoco Remedies reported a consolidated net loss of ₹986.84 crore for FY26, significantly wider than the previous year's loss of ₹779.51 crore, despite revenue growth to ₹1,845.32 crore from ₹1,664.92 crore. The loss was driven by increased finance costs of ₹122.25 crore (up from ₹66.23 crore) and higher operating expenses. Standalone performance showed revenue of ₹1,686.07 crores but net loss of ₹5.66 crores due to strategic investments.
Balance Sheet and Debt Position
The company's borrowings increased to ₹1,035.84 crore, with net debt-to-equity ratio rising to 113.4% from 95.9% in the prior year. Non-current borrowings stood at ₹665.99 crore comprising secured term loans, while current borrowings totaled ₹519.83 crore including cash credit facilities and working capital loans. Cash equivalents stood at ₹25.93 crore with net cash increase of ₹13.82 crore during the year.
Operational and Business Performance
Indoco maintained its 33rd position in the Indian Pharmaceutical Market with 40 products ranking in the top 5 of their segments, generating 109 million prescriptions from 2.5 lakh prescribers. The company secured 4 ANDA approvals for the US market and completed a successful USFDA inspection with zero observations at its Patalganga API facility. International operations saw successful launches in North America and new tenders won in European markets.
Research and Development Investments
R&D expenditure remained high at 4.9% of net sales (₹79.5 crores) with 5 new patent applications filed (1 API, 4 FDFs), bringing the total patent portfolio to 123 applications and 54 granted patents. Significant additions were made to property, plant and equipment (₹74.25 crore) and intangible assets (₹67.14 crore), including ₹44.08 crore in intangible assets under development.
Corporate Structure and Compliance
The group consists of five subsidiaries including Warren Remedies, Xtend Industrial Designers, Indoco Remedies Czech, Indoco Remedies UK, and FPP Holding Company (85% ownership). The financial statements received unmodified audit opinion from Gokhale & Sathe, with key audit matters relating to provisions for sales returns (₹2,444.82 lakhs) and intangible assets under development (₹6,172.25 lakhs). Contingent liabilities include GST matters of ₹3,258.79 lakhs and various tax demands.